Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies —Analysis of the WHO Pharmacovigilance Database
ConclusionRhabdomyolysis reporting was increased when ticagrelor -but not other antiplatelet agents- was notified with the most prescribed statins in practice. This finding needs to be considered by physicians especially in high-risk patients.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Aspirin | Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Clopidogrel | Crestor | Databases & Libraries | Fluvastatin | Heart | International Medicine & Public Health | Lipitor | Plavix | Pravastatin | Rhabdomyolysis | Rosuvastatin | Simvastatin | Statin Therapy | WHO | Zivast | Zocor